Pediatrix Medical Group, Inc. (MD) — Fair Value Analysis

Base-case fair value (P50): $18.25 · Current price: $23.61 · Verdict: Overvalued

The Verdict on MD

PEDIATRIX MEDICAL GROUP INC (MD) is currently assessed as Fairly Valued based on our proprietary Monte Carlo simulations. The current market price of $23.61 sits above our median fair value (P50) of $18.25, indicating a -22.7% difference. This outcome suggests that while MD is not significantly overvalued, its shares are trading at a slight premium to the central tendency of our probabilistic models, which integrate a comprehensive range of potential future scenarios. The Fairly Valued verdict provides a balanced perspective on its current market positioning.

How MD stacks up against peers

Our analysis places PEDIATRIX MEDICAL GROUP INC in an average quality tier, reflecting its operational and financial health when assessed against broader market benchmarks, even without a specific sector designation. This average quality is a key input into our Monte Carlo simulations, which generate the $18.25 fair value from thousands of forward-looking scenarios. The fact that $23.61 trades with a -22.7% difference from $18.25 suggests the market's current valuation of MD closely mirrors, yet slightly exceeds, the value implied by its fundamental quality and our simulated median outcome.

What this means for investors

For investors evaluating PEDIATRIX MEDICAL GROUP INC, the current $23.61 relative to the $18.25 fair value, along with the -22.7% indicator, points to a somewhat elevated, yet still "Fairly Valued," position. This means that while MD is not severely mispriced, potential upside appears limited under a median scenario. Investors seeking deeper insights into the full range of probabilistic outcomes, including detailed bear and bull case scenarios, will find value in our tools. Sign up for a free FairCurve account to access the complete Monte Carlo distribution and track MD's fair value as new fundamentals are released.